TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03519048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasofibroscopy
Description: every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Chest CTscan
Description: every year in patients with tobacco consumption history of \> 20 pack-year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injected CT-scan
Description: the first performed 12 months after inclusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body PET-CT
Description: annual whole body PET-CT (the first at 6 months after inclusion)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lugol upper gastrointestinal endoscopy
Description: the first performed 12 months after inclusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: In both arm, patient will have a confirmation biopsy in case of suspicion of relapse or second primary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: In both arm, patient will have a confirmation biopsy in case of suspicion of relapse or second primary.
Study: NCT02109237

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of sleep disorders and treatment if required
Description: Assessment of sleep disorders and treatment if required

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment of sleep disorders and treatment if required
Description: Assessment of sleep disorders and treatment if required
Study: NCT02886429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Ultrasound guided paravertebral block with bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Ultrasound guided paravertebral block with bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Ultrasound guided paravertebral block with dexmedetomidine
Study: NCT00783627

Intervention type: PROCEDURE
Intervention: Angiography
Description: Angiography done at the J1 visit
Study: NCT00840632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trandolapril 4 mg Tablets
Description: 1 x 4 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mavik® 4 mg Tablets
Description: 1 x 4 mg, single-dose fasting
Study: NCT01334307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Coil (LVRC) (PneumRx)
Description: Lung Volume Reduction Coil (LVRC)
Study: NCT01886560

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets placebo one PO per day for 12 weeks
Study: NCT02538198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT03841981

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral smear and feces specimen
Description: Microbiome studies.
Study: NCT02300480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTB group
Description: CTB: A single injection of 1.0% 10ml ropivacaine by bile duct needle in calot's triangle when before surgical dissection.After surgery,participants in this group will also receive PCIA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCIA group
Description: The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
Study: NCT04376697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The treatment will be delivered by trained medical personnel.
Study: NCT01280240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monofer(R)
Description: Intravenous bolus injection given over app. 2 minutes only once
Study: NCT01334307

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard of Care
Study: NCT00249496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Employment Only
Description: Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
Study: NCT04215393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept eye drop
Description: In the first stage, subjects will be receive Conbercept eye drop. In the second stage,subjests will revceive conbercept eye drop or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept eye drop
Description: In the first stage, subjects will be receive Conbercept eye drop. In the second stage,subjests will revceive conbercept eye drop or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept eye drop
Description: In the first stage, subjects will be receive Conbercept eye drop. In the second stage,subjests will revceive conbercept eye drop or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In the second stage, subjects will be receive Conbercept eys drop or a placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In the second stage, subjects will be receive Conbercept eys drop or a placebo.
Study: NCT02605382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
Study: NCT02293174

Intervention type: DEVICE
Intervention: Topcon TRC-NW400
Description: Retinal Fundus Camera

Intervention type: DEVICE
Intervention: TRC-NW8
Description: Retinal Fundus Camera

Intervention type: DEVICE
Intervention: TRC-NW400
Description: Retinal Fundus Camera

Intervention type: DEVICE
Intervention: Canon-CR2
Description: Retinal Fundus Camera

Intervention type: DEVICE
Intervention: Zeiss Visucam PRO
Description: Retinal Fundus Camera
Study: NCT04227860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercise program
Description: Patients will be engaged in lower extremity kinesthesia and balance exercise program 3 time per week for 6 weeks.~Divided into 2 stages, stage 1 and 2, each stage 3 weeks. Patients who fulfill at least stage 1 of the program will be included in the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercise program
Description: Patients will be engaged in lower extremity kinesthesia and balance exercise program 3 time per week for 6 weeks.~Divided into 2 stages, stage 1 and 2, each stage 3 weeks. Patients who fulfill at least stage 1 of the program will be included in the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercise program
Description: Patients will be engaged in lower extremity kinesthesia and balance exercise program 3 time per week for 6 weeks.~Divided into 2 stages, stage 1 and 2, each stage 3 weeks. Patients who fulfill at least stage 1 of the program will be included in the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercise program
Description: Patients will be engaged in lower extremity kinesthesia and balance exercise program 3 time per week for 6 weeks.~Divided into 2 stages, stage 1 and 2, each stage 3 weeks. Patients who fulfill at least stage 1 of the program will be included in the study.
Study: NCT00467896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost PD-6
Description: Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost PD-15
Description: Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.
Study: NCT03548519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OCAT-only
Description: online-contingent Attention Training without prior psychoeducation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OCAT-sham
Description: Placebo version of Online contingent Attention Training without prior psychoeducation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OCAT-combo
Description: Online contingent Attention Training with prior psychoeducation
Study: NCT01027923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Study: NCT04227860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercise program
Description: Patients will be engaged in strengthening exercise program 3 time per week for 6 weeks.~Divided into 3 stages, stage 1, 2 and 3, each stage 2 weeks. Patients who fulfill at least stage 1 of the program will be included in the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercise program
Description: Patients will be engaged in strengthening exercise program 3 time per week for 6 weeks.~Divided into 3 stages, stage 1, 2 and 3, each stage 2 weeks. Patients who fulfill at least stage 1 of the program will be included in the study.
Study: NCT01027923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study: NCT00077350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01027923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study: NCT01481025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimicifuga + Hiperico
Description: 1 tablet, 80+450mg/tablet, twice a day for 1-3 months~1 tablet, 80+450mg/tablet, once a day for 3-6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimicifuga Herbarium
Description: 2 caps, 80mg/caps, once a day for 1-3 months~1 caps, 80mg/caps, once a day for 3-6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aplause®
Description: 4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months
Study: NCT03743818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry needling
Description: dry needling on the trigger point of the vastus medialis of the quadriceps
Study: NCT01027923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study: NCT02975622

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central venous catheterization
Description: Ultrasound guided central venous catheterization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central venous catheterization
Description: Ultrasound guided central venous catheterization
Study: NCT00420303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg injection once weekly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01394497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcystein
Description: 15 min systemic NAC infusion of the donor (30 mg/kg, maximum dose 3000 mg) diluted into 500 ml 5 % glucose solution, 30 min before initiating the liver harvesting procedure, and a loco-regional infusion (150 mg/kg of estimated liver weight, maximum dose 300 mg) into the portal vein 5 min before cross-clamping.
Study: NCT03743818

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: aply ultrasound on the knee

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyauluronic acid
Description: aply hyaluronic acid on the knee
Study: NCT04676230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Caries management based on the ICCMSTM: Patient intervention according to the caries risk likelihood: high, moderate or low. Surfaces intervention according to the surface diagnosis decision matrix (ICCMSTM): Mi: Initial caries management, Mm: Moderate caries management, and Me: Extensive caries management.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Systematic patient caries risk intervention (all managed as high risk patients). Surfaces intervention with conventional caries management of cavitated/dentin caries lesions (restorative treatment).
Study: NCT03544411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: olive oil
Description: the intervention consist of 15 ml / day of olive oil
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A (ALS-008176)
Description: Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.
Study: NCT03544411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: olive oil
Description: the intervention consist of 15 ml / day of olive oil

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bran oil
Description: the intervention consist of 15 ml / day of bran oil

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bran oil
Description: the intervention consist of 15 ml / day of bran oil
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A (ALS-008176)
Description: Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A (ALS-008176)
Description: Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A (ALS-008176)
Description: Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A (ALS-008176)
Description: Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A (ALS-008176)
Description: Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.
Study: NCT04587570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infiltration with PRP
Description: Infiltration with 1.5 ml PRP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infiltration with Fat
Description: Infiltration with 1.5 ml Fat
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
Study: NCT01086787

Intervention type: OTHER
Intervention: Surgery
Description: Patients undergoing surgery for either cardiac surgery or orthopedic surgery

Intervention type: OTHER
Intervention: Surgery
Description: Patients undergoing surgery for either cardiac surgery or orthopedic surgery

Intervention type: OTHER
Intervention: Surgery
Description: Patients undergoing surgery for either cardiac surgery or orthopedic surgery
Study: NCT00635622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIN-V
Description: Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10\^9 cfu/dose or placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control substance
Description: Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
Study: NCT03248921

Intervention type: PROCEDURE
Intervention: cardiac surgery
Description: cardiac surgery including non-emergency, elective coronary artery bypass grafting surgery with or without valve surgery, aortic or mitral valve surgery

Intervention type: PROCEDURE
Intervention: cardiac surgery
Description: cardiac surgery including non-emergency, elective coronary artery bypass grafting surgery with or without valve surgery, aortic or mitral valve surgery
Study: NCT03295825

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biomarker
Description: Measument of heparin-binding protein in the serum of patients
Study: NCT00743795

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9190
Description: 40 mg oral BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9190
Description: 40 mg oral BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon Alfa 2a
Description: All subjects received a fixed dose of 180 μg PEG via subcutaneous injection on a weekly basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa 2a
Description: All subjects received a fixed dose of 180 μg PEG via subcutaneous injection on a weekly basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa 2a
Description: All subjects received a fixed dose of 180 μg PEG via subcutaneous injection on a weekly basis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin supplied as 200 mg Copegus® tablets (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) were given in a divided daily dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin supplied as 200 mg Copegus® tablets (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) were given in a divided daily dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin supplied as 200 mg Copegus® tablets (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) were given in a divided daily dose.
Study: NCT01995890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nepafenac
Study: NCT00558090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: patients receive 7,5 mg morphine iv 30 minutes before intervention (turning of the patient), the day after admission in the ICU. before, during and after, the patient will be asked to rate the pain using the NRS
Study: NCT00681551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnevist (SH L 451A)
Description: Magnevist at a dose of 0.1 mmol/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnevist (SH L 451A)
Description: Magnevist at a dose of 0.1 mmol/kg and another 0.1 mmol/kg 30minutes later.
Study: NCT05495607

Intervention type: DEVICE
Intervention: CARPEDIEN
Description: Continuous renal replacement therapy
Study: NCT00444015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib in combination with Dasatinib
Description: 6 Cycles @ 28 Days
Study: NCT01027689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam commercial immediate release oral tablet
Description: 1 mg tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam test sublingual tablet
Description: 1 mg tablet, single dose